Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zirconium Zr 89-DFO-cRGDY PEG-Cy5-C' dots
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Zirconium Zr 89-DFO-cRGDY PEG-Cy5-C' dots is a radioconjugate composed of ultrasmall silica-based nanoparticles labeled with zirconium-89 (89Zr) and a near-infrared (NIR) fluorophore (Cy5). The particles are functionalized with the cyclic peptide cRGDY that targets αvβ3 integrin receptors, which are overexpressed in many tumor types. This dual-modality (PET-optical) imaging agent allows for both positron emission tomography (PET) imaging and fluorescence detection. The particles feature favorable pharmacokinetic properties including renal clearance and limited retention in the reticuloendothelial system (RES), with blood circulation half-lives of approximately 15 hours. The ultrasmall size and surface properties of these particles enable them to effectively penetrate tumors while maintaining target specificity.
- Other names
- cRGDY-PEG-[89Zr]C′ dots
02
Targets
αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on zirconium Zr 89-DFO-cRGDY PEG-Cy5-C' dots.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zirconium Zr 89-DFO-cRGDY PEG-Cy5-C' dots.